Market revenue in 2020 | USD 114.1 million |
Market revenue in 2028 | USD 235.1 million |
Growth rate | 9.5% (CAGR from 2020 to 2028) |
Largest segment | Recombinant vaccine |
Fastest growing segment | Recombinant vaccine |
Historical data | 2017 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Recombinant vaccine |
Key market players worldwide | Zoetis, Phibro Animal Health Corp Class A, Elanco Animal Health Inc, Merck & Co Inc, KBNP, Choong Ang Vaccine Laboratories (CAVAC), Kyoto Biken Laboratories, Nissenken, Vaxxinova, HIPRA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dna vaccines market will help companies and investors design strategic landscapes.
Recombinant vaccine was the largest segment with a revenue share of 100% in 2020. Horizon Databook has segmented the Australia dna vaccines market based on recombinant vaccine covering the revenue growth of each sub-segment from 2017 to 2028.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia dna vaccines market , including forecasts for subscribers. This country databook contains high-level insights into Australia dna vaccines market from 2017 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account